M

Mineralys Therapeutics Inc
NASDAQ:MLYS

Watchlist Manager
Mineralys Therapeutics Inc
NASDAQ:MLYS
Watchlist
Price: 36.83 USD -0.83%
Market Cap: 2.9B USD

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of MLYS.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MLYS Intrinsic Value
Not Available
Base Case Scenario
Compare MLYS to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about MLYS?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Mineralys Therapeutics Inc

Current Assets 599.8m
Cash & Short-Term Investments 593.6m
Other Current Assets 6.2m
Non-Current Assets 151k
PP&E 7k
Other Non-Current Assets 144k
Current Liabilities 23.5m
Accounts Payable 1.1m
Accrued Liabilities 22.4m
Efficiency

Free Cash Flow Analysis
Mineralys Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Mineralys Therapeutics Inc

Revenue
0 USD
Operating Expenses
-184.1m USD
Operating Income
-184.1m USD
Other Expenses
12.7m USD
Net Income
-171.4m USD
Fundamental Scores

MLYS Profitability Score
Profitability Due Diligence

Mineralys Therapeutics Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
Negative ROE
hidden
Profitability
Score

Mineralys Therapeutics Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.

MLYS Solvency Score
Solvency Due Diligence

Mineralys Therapeutics Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
hidden
Solvency
Score

Mineralys Therapeutics Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MLYS Price Targets Summary
Mineralys Therapeutics Inc

Wall Street analysts forecast MLYS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MLYS is 50.62 USD with a low forecast of 42.42 USD and a high forecast of 58.8 USD.

Lowest
Price Target
42.42 USD
15% Upside
Average
Price Target
50.62 USD
37% Upside
Highest
Price Target
58.8 USD
60% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Mineralys Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MLYS is hidden .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
HIDDEN
Show
Dividend Yield
No dividends
Buyback Yield
HIDDEN
Debt Paydown Yield
HIDDEN

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

MLYS Insider Trading
Buy and sell transactions by insiders